NO20043833L - Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser. - Google Patents

Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser.

Info

Publication number
NO20043833L
NO20043833L NO20043833A NO20043833A NO20043833L NO 20043833 L NO20043833 L NO 20043833L NO 20043833 A NO20043833 A NO 20043833A NO 20043833 A NO20043833 A NO 20043833A NO 20043833 L NO20043833 L NO 20043833L
Authority
NO
Norway
Prior art keywords
activity
serotonin
compounds
combination
well
Prior art date
Application number
NO20043833A
Other languages
English (en)
Norwegian (no)
Inventor
Gustaaf Johan Mar Scharrenburg
Roelof W Feenstra
Eric Ronken
Andrew C Mccreary
Juliana B Bronzova
Jeffrey C Giennon
Jan Van Randen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20043833L publication Critical patent/NO20043833L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20043833A 2002-02-14 2004-09-13 Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser. NO20043833L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020076344 EP1336406A1 (de) 2002-02-14 2002-02-14 Partieller Dopamin-D2 Rezeptoragonist plus Substanzen mit Serotonin- und/oder Noradrenalin inhibitorischer Aktivität
PCT/EP2003/050015 WO2003068207A2 (en) 2002-02-14 2003-02-11 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity

Publications (1)

Publication Number Publication Date
NO20043833L true NO20043833L (no) 2004-09-13

Family

ID=27619173

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043833A NO20043833L (no) 2002-02-14 2004-09-13 Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser.

Country Status (16)

Country Link
US (1) US20050038015A1 (de)
EP (2) EP1336406A1 (de)
JP (1) JP2005517036A (de)
KR (1) KR20040081779A (de)
CN (1) CN1592614A (de)
AU (1) AU2003208714A1 (de)
BR (1) BR0306147A (de)
CA (1) CA2462688A1 (de)
HR (1) HRP20040276A2 (de)
IL (1) IL160942A0 (de)
MX (1) MXPA04004745A (de)
NO (1) NO20043833L (de)
PL (1) PL370632A1 (de)
RU (1) RU2004112546A (de)
WO (1) WO2003068207A2 (de)
ZA (1) ZA200404740B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200460T2 (tr) 1999-08-23 2002-06-21 Solvay Pharmaceuticals B.V. Yeni fenilpiperazinler
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
AR032712A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
EP2036547A3 (de) 2001-07-20 2009-12-23 Psychogenics Inc. Behandlung von Hyperaktivitätsstörungen mit Aufmerksamkeitsdefiziten
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1723957A3 (de) 2002-12-27 2013-01-23 Otsuka Pharmaceutical Co., Ltd. Carbostyril-Derivate mit selektiven Serotonin-Aufnahme Inhibitoren, zur Behandlung von Gemütskrankheiten
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
EP1595542A1 (de) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermale iontophoretische Verabreichung von Piperazinyl-2(3H)-benzoxazolon-Verbindungen
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
WO2007019880A1 (en) * 2005-08-18 2007-02-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome
WO2007065713A2 (en) * 2005-12-08 2007-06-14 Axxonis Pharma Gmbh Use of 8-alpha-ergolines for the treatment of traumatic brain disorders
AU2008279572A1 (en) 2007-02-01 2009-01-29 David Chau Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
EP2182952A4 (de) * 2007-07-23 2010-09-08 Synosia Therapeutics Behandlung von posttraumatischen stresszuständen
TW200936130A (en) * 2008-02-26 2009-09-01 Lundbeck & Co As H Uses of indane compounds
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
BR112012026471A2 (pt) * 2010-04-19 2016-11-29 Nlife Therapeutics S L conjugado, processo para a síntese do mesmo, método para imagem de uma célula que expressa um transportador de neurotransmissor que compreende o contato da referida célula com o conjugado, processo para preparar um comporto de fórmula (ii) e (xiv) e composto
CN111134894B (zh) * 2020-01-17 2022-02-22 上海长海医院 一种在体测定犬前列腺组织连续动态游离药物浓度的采样方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
TR200200460T2 (tr) * 1999-08-23 2002-06-21 Solvay Pharmaceuticals B.V. Yeni fenilpiperazinler

Also Published As

Publication number Publication date
WO2003068207A2 (en) 2003-08-21
CN1592614A (zh) 2005-03-09
EP1336406A1 (de) 2003-08-20
IL160942A0 (en) 2004-08-31
AU2003208714A1 (en) 2003-09-04
EP1476148A2 (de) 2004-11-17
US20050038015A1 (en) 2005-02-17
MXPA04004745A (es) 2004-08-02
PL370632A1 (en) 2005-05-30
KR20040081779A (ko) 2004-09-22
JP2005517036A (ja) 2005-06-09
WO2003068207A3 (en) 2003-12-18
BR0306147A (pt) 2004-10-19
CA2462688A1 (en) 2003-08-21
RU2004112546A (ru) 2005-03-27
ZA200404740B (en) 2005-08-23
HRP20040276A2 (en) 2005-04-30

Similar Documents

Publication Publication Date Title
NO20043833L (no) Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser.
AP2001002252A0 (en) Monoamine reuptake inhibitors for treatment of CNS disorders.
WO2004047830A3 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
NO20120150L (no) Bifenylderivat, farmasoytisk sammensetning omfattende samme samt anvendelse av samme til behandling av en pulmonal lidelse
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
MY148002A (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
HK1199253A1 (en) Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof toblock reuptake of norepinephrine, dopamine, and serotonin
NL1026044A1 (nl) Inwendige roterende regelkop voor stijgbuis.
WO2006014918A3 (en) Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
PT1833799E (pt) Derivados de 3-fenil-pirazole como moduladores do receptor 5-ht2a de serotonina úteis no tratamento de desordens que lhe estão relacionadas
BRPI0511527A (pt) compostos e composições como moduladores de ppar
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
AU2003254343A1 (en) Benzothiophene urea, benzofurane urea, and indole urea, and use of the same as alpha-7 achr agonists
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
IL225745A0 (en) Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds are suitable for the treatment of disorders that respond to dopamine 3d receptor regulation
WO2004052858A3 (en) Inhibitors of monoamine uptake
WO2007071442A3 (en) Inhibitors of ccr9 activity
IL176238A0 (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
IL190783A0 (en) Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders
AU2003259759A1 (en) Gal3 receptor antagonists for the treatment of affective disorders
EP1633306A4 (de) Verwendung von phosphatase-hemmern als adjunktive therapie bei psychischen störungen
ITRM20050127A1 (it) Uso di inibitori dell'attivita' degli steroidi per il trattamento di disturbi correlati a sostanze.
UA85198C2 (ru) Производные морфолина как ингибиторы повторного поглощения норэпинефрина